<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8639011
   </pmid>
   <datecreated>
    <year>
     1996
    </year>
    <month>
     07
    </month>
    <day>
     11
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1996
    </year>
    <month>
     07
    </month>
    <day>
     11
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-9926
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       156
      </volume>
      <issue>
       11
      </issue>
      <pubdate>
       <year>
        1996
       </year>
       <month>
        Jun
       </month>
       <day>
        10
       </day>
      </pubdate>
     </journalissue>
     <title>
      Archives of internal medicine
     </title>
     <isoabbreviation>
      Arch. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Testosterone therapy in glucocorticoid-treated men.
    </articletitle>
    <pagination>
     <medlinepgn>
      1173-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Treatment with glucocorticoid drugs is a valuable therapy, but the use of these drugs is associated with major side effects, including osteoporosis, muscle wasting, and obesity. In men who take glucocorticoids, circulating testosterone concentrations are reduced, and this might contribute to the changes in bone and soft-tissue mass.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To asses the effect of testosterone replacement on these above-mentioned parameters in glucocorticoid-treated men.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Fifteen asthmatic men who were receiving long-term glucocorticoid treatment were randomly allocated to receive therapy with testosterone esters (30 mg of proprionate, 60 mg of phenylprionate, 60 mg of isocaproate, and 100 mg of decanoate [Sustanon]) (250-mg/mo intramuscular depot injection) or to act as control subjects during 12 months. After a washout period for those men who were receiving testosterone, the groups were then crossed over and studied for a further 12 months. Bone density and body composition were assessed by dual-energy, x-ray absorptiometry. Paired or unpaired 2-tailed t tested were calculated. Unless otherwise stated, all values are given as mean +/- SEM.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Bone density in the lumbar spine increased 5.0% +/- 1.4% (mean +/- SEM) (P = .005) during testosterone supplementation, but it did not change during the control period (between-groups difference, P = .05). These changes were accompanied by a decrease in the indexes of bone turnover. There was a gain in body fat mass (2.1 +/- 0.06 kg, P = .01) and a loss of lean body mass (1.4 +/- 0.5 kg, P = .02) during the control period, with both changes being reversed by testosterone treatment (P &lt; .03).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Testosterone treatment reverses the deleterious effects glucocorticoid drugs on skeletal and soft tissues in men.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, University of Auckland (New Zealand).
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Reid
      </lastname>
      <forename>
       I R
      </forename>
      <initials>
       IR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wattie
      </lastname>
      <forename>
       D J
      </forename>
      <initials>
       DJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Evans
      </lastname>
      <forename>
       M C
      </forename>
      <initials>
       MC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stapleton
      </lastname>
      <forename>
       J P
      </forename>
      <initials>
       JP
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Arch Intern Med
    </medlineta>
    <nlmuniqueid>
     0372440
    </nlmuniqueid>
    <issnlinking>
     0003-9926
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Glucocorticoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Lipids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      58-22-0
     </registrynumber>
     <nameofsubstance>
      Testosterone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7440-70-2
     </registrynumber>
     <nameofsubstance>
      Calcium
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Arch Intern Med. 1996 Jun 10;156(11):1133-4
     </refsource>
     <pmid version="1">
      8639006
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Asthma
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Body Composition
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Density
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Calcium
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glucocorticoids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      antagonists &amp; inhibitors
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lipids
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Testosterone
     </descriptorname>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      10
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      10
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      10
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8639011
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

